Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 5,500 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 5,500 shares of Akero Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $27.65, for a total value of $152,075.00. Following the completion of the transaction, the insider now owns 75,294 shares of the company’s stock, valued at $2,081,879.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total value of $106,684.76.
• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.52, for a total value of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.53, for a total transaction of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Stock Performance

Shares of NASDAQ AKRO opened at $28.05 on Wednesday. Akero Therapeutics, Inc. has a 1 year low of $11.25 and a 1 year high of $51.24. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. The stock has a fifty day moving average price of $26.36 and a two-hundred day moving average price of $23.83. The firm has a market cap of $1.94 billion, a P/E ratio of -8.77 and a beta of -0.26.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. Research analysts forecast that Akero Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.

Institutional Trading of Akero Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its stake in Akero Therapeutics by 42.2% in the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock worth $154,589,000 after acquiring an additional 1,815,569 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Akero Therapeutics by 10.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock worth $102,569,000 after purchasing an additional 384,555 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Akero Therapeutics by 19.0% during the first quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock worth $92,702,000 after purchasing an additional 584,875 shares during the period. RTW Investments LP purchased a new position in Akero Therapeutics during the fourth quarter valued at approximately $83,891,000. Finally, Wellington Management Group LLP increased its stake in Akero Therapeutics by 247.7% in the 4th quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock valued at $67,294,000 after buying an additional 2,053,028 shares during the period.

Analysts Set New Price Targets

Several brokerages have commented on AKRO. Wolfe Research started coverage on shares of Akero Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a report on Tuesday, September 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.13.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.